Ticker LaunchIPO · IMRX
Immuneering Corp
Immuneering Corp (IMRX) priced its initial public offering on Jul 30, 2021 at $15.00 per share, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $365.8M. Latham & Watkins advised the company and Sidley Austin advised the underwriters.
Immuneering Corp is a biopharmaceutical company with a pipeline in oncologic and neurologic diseases. It applies translational bioinformatics, using human data, biology and chemistry on a disease-agnostic platform, to develop its wholly owned medicines.
- Status
- IPO
- Ticker
- IMRX
- Exchange
- Nasdaq Global Market
- Priced
- Jul 30, 2021
- IPO price
- $15.00
- Market cap at IPO price
- $365.8M
- First filed
- Jul 9, 2021
- Company counsel
- Latham & Watkins
- Underwriters' counsel
- Sidley Austin
- Sector
- Biotech & pharma
- Country / state
- MA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed Jul 9, 2021
- Latest amendment Jul 28, 2021
- Final prospectus (424B4) Jul 30, 2021
- All filings on EDGAR CIK 1790340
Other Biotech & pharma IPOs in 2021
- Icosavax, Inc.ICVX · Jul 30, 2021 · $182M
- Maxcyte, Inc.MXCT · Jul 30, 2021
- Nuvalent, Inc.NUVL · Jul 30, 2021 · $16.6M
- Rallybio CorpRLYB · Jul 30, 2021 · $80.6M
- Tenaya Therapeutics, Inc.TNYA · Jul 30, 2021 · $180M
- Candel Therapeutics, Inc.CADL · Jul 28, 2021 · $72M